The Cochrane Library and safety of regular long-acting beta2- agonists in children with asthma: An overview of reviews

Evidence-Based Child Health

Volumn 7, Issue 6, 2012, Pages 1798-1806

  Cates, Christopher J ^a   Stovold, Elizabeth ^a   Wieland, Susan ^b   Oleszczuk, Marta ^c   Thomson, Denise ^c   Becker, Lorne ^d  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

^d State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

Asthma; Cochrane Library; LABA; Long acting beta2 agonist; Overview; Safety

Indexed keywords

EID: 84868627138     PISSN: None     EISSN: 15576272     Source Type: Journal    
DOI: 10.1002/ebch.1889     Document Type: Article

References (25)

1. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2011; Available at: ww.ginasthma.org [accessed 20 July 2012].
2. Scottish Intercollegiate Guidelines Network/British Thoracic Society. British Guideline on the Management of Asthma: A National Clinical Guideline. Edinburgh: Scottish Intercollegiate Guidelines Network; 2008; (revised 2012).
3. Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993; 306: 1034-1037. Epub 17 April 1993.
4. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129: 15-26. Epub 21 January 2006.
5. Tattersfield AE. Current issues with beta2-adrenoceptor agonists: historical background. Clin Rev Allergy immunol 2006; 31: 107-118. Epub 7 November 2006.
6. Weinberger M, Abu-Hasan M. Life-threatening asthma during treatment with salmeterol. N Engl J Med 2006; 355: 852-853. Epub 25 August 2006.
7. Fogel RB, Rosario N, Aristizabal G, Loeys T, Noonan G, Gaile S, et al. Effect of montelukast or salmeterol added to inhaled fluticasone on exercise-induced bronchoconstriction in children. Ann Allergy Asthma Immunol 2010; 104: 511-517. Epub 24 June 2010.
8. McMahon AW, Levenson MS, McEvoy BW, Mosholder AD, Murphy D. Age and risks of FDA-approved long-acting beta(2)-adrenergic receptor agonists. Pediatrics 2011; 128: e1147-e1154. Epub 26 October 2011.
9. Lougheed MD, Lemiere C, Dell S, Ducharme F, Fitzgerald JM, Leigh R, et al. Canadian Thoracic Society Asthma Committee commentary on long-acting beta-2 agonist use for asthma in Canada. Can Respir J 2010; 17: 57-60. Epub 28 April 2010.
10. Cates CJ, Oleszczuk M, Stovold E, Wieland LS. The safety of regular formoterol or salemeterol in children with asthma: an overview of Cochrane reviews. Cochrane Database Syst Rev 2012; Issue 7: Art. No.: CD010005.
11. Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol 2007; 7: 10. Epub 17 February 2007.
12. ICHE2a. Expert Working Group (Efficacy) of International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Clinical Safety Data Management: Definition and Standards for expedited reporting. Available at: http://www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatoryInformation/Guidances/ucm073087.pdf 1995 [accessed on 22 August 2012].
13. Cates CJ, Cates MJ. Regular treatment with salmeterol for chronic asthma: serious adverse events. Cochrane Database Syst Rev 2008; Issue:(3):Art No.: CD006363. Epub 23 July 2008.
14. Cates CJ, Cates MJ. Regular treatment with formoterol for chronic asthma: serious adverse events. Cochrane Database Syst Rev 2012; 4: CD006923. Epub 20 April 2012.
15. Cates CJ, Lasserson TJ. Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events. Cochrane Database Syst Rev 2010; Issue(1):Art No.: CD007694. Epub 22 January 2010.
16. Cates CJ, Lasserson TJ. Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events. Cochrane Database Syst Rev 2012; 3: CD007695. Epub 16 March 2012.
17. Cates CJ, Lasserson TJ, Jaeschke R. Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database Syst Rev 2009; Issue(3):Art No.: CD006922. Epub 10 July 2009.
18. Cates CJ, Lasserson TJ, Jaeschke R. Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database Syst Rev 2009; Issue(2):Art No.: CD006924. Epub 17 April 2009.
19. Li J, Py Q, Weinstein S, LaForce C, Ellsworth A, Ortega H, et al. Fluticasone propionate/salmeterol combination in children with asthma: key cardiac and overall safety results. Clin Res Regul Aff 2010; 27: 87-95.
20. NCT01192178. GlaxoSmithKline. A Randomized, Double-Blind, Parallel Group Study of FCS100/50 and FP 100, Both Twice Daily, in a Pediatric Population during the Fall Viral Season [ADA113872] 2012; Available at: http://www.gsk-clinicalstudyregister.com [accessed 20 July 2012].
21. Cates CJ. Visul Rx. 2012; Available at: www.nntonline.net/visualrx [accessed 20 July 2012].
22. AstraZeneca. A 6 Month Safety Study Comparing Symbicort with Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents. Clinicaltrialsgov2012. 2012.
23. SAS115359 G. A 6-Month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared with Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) with Asthma. (AUSTRI). ClinicalTrialsgov2012. 2012.
24. GlaxoSmithKline. 6-Month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old (VESTRI). ClinicalTrialsgov2012. 2012.
25. Mreck. A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241 AM3) (SPIRO). ClinicalTrialsgov2012. 2012.